Across TCGA pan-cancer cohorts, LDHD Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LDHD data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher LDHD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LDHD expression acts as an unfavorable survival marker.
ESCA and BLCA are the cancer types where LDHD Mutation most reproducibly stratifies survival.